FindTrial
Sign In

Post-marketing clinical trial of Pegasys 180ug for subcutaneous injection (s.c.) in patients with chronic hepatitis C. -General clinical study in IFN-treated or IFN-untreated chronic hepatitis C patients, except for those infected with genotype 1b of hepatitis C virus and a high viral load.

Post-marketing clinical trial of Pegasys 180ug for subcutaneous injection (s.c.) in patients with chronic hepatitis C. -General clinical study in IFN-treated or IFN-untreated chronic hepatitis C patients, except for those infected with genotype 1b of hepatitis C virus and a high viral load.

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220157
Enrollment
Unknown
Registered
2005-10-24
Start date
2005-10-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

investigational material(s) Generic name etc : PEGASYS 180ug for s.c. INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Over 20 years old of male and female patients with chronic hepatitis C except for those infected with genotype 1b and a high viral load (>= 100 KIU/mL).And the patient shows positive serum HCV-RNA, and increase of serum ALT above the normal upper limit of the site.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026